{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:49:09Z","timestamp":1792021749828,"version":"4.4.0"},"reference-count":112,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Vet Emergen Crit Care"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective \u2013<\/jats:bold>To review the human and veterinary literature on the pathophysiology of myasthenia gravis (MG) and describe treatment options for clinical use in people and animals.<\/jats:p><jats:p><jats:bold>Data Sources \u2013<\/jats:bold>Human and veterinary clinical reports, studies and reviews, textbooks, and recent research findings in MG from 1996 present, with a focus on treatment and patient management.<\/jats:p><jats:p><jats:bold>Human Data Synthesis \u2013<\/jats:bold>MG is a well\u2010described condition in people with new research and treatment options available. Many of the newest therapeutic options available in veterinary medicine for MG are based on current strategies used in people with this condition. Seronegative MG is well described in people and provides insight to clinical cases encountered in veterinary medicine when the index of suspicion is high though serologic tests are negative.<\/jats:p><jats:p><jats:bold>Veterinary Data Synthesis \u2013<\/jats:bold>Previous studies in veterinary medicine focused on the use of acetylcholinesterase inhibitors as the main form of treatment in canine MG. Recent studies, mainly case series and case reports, emphasize the use of immunomodulatory treatments as an alternative for long\u2010term treatment. However, there are no randomized, controlled studies on treatment with immunomodulatory therapy for MG in dogs available to assess the efficacy of this treatment strategy.<\/jats:p><jats:p><jats:bold>Conclusions \u2013<\/jats:bold>Although early recognition of clinical signs is most important in the outcome of patients with MG, further understanding the pathophysiology of MG may lead to earlier diagnosis and novel treatment strategies. The discovery of additional autoantibodies against striated muscle proteins in dogs, should enhance our understanding of diseases affecting the neuromuscular junction. In addition, clinical data for canine MG could be applied to other autoimmune disorders.<\/jats:p>","DOI":"10.1111\/j.1476-4431.2011.00636.x","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T11:28:46Z","timestamp":1305026926000},"page":"193-208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Myasthenia gravis in dogs with an emphasis on treatment and critical care management"],"prefix":"10.1111","volume":"21","author":[{"given":"Roxanna","family":"Khorzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Sisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,10]]},"reference":[{"key":"e_1_2_26_2_2","volume-title":"BSAVA Manual of Canine and Feline Neurology","author":"Platt SR","year":"2004"},{"key":"e_1_2_26_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05186-2"},{"key":"e_1_2_26_4_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom JM.","year":"2000","journal-title":"Muscle Nerve"},{"key":"e_1_2_26_5_2","first-page":"41","article-title":"Nicotinic acetylcholine receptors of muscles and nerves","volume":"998","author":"Lindstrom JM.","year":"2003","journal-title":"comparison of their structures, functional roles, and vulnerability to pathology"},{"key":"e_1_2_26_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(03)00085-8"},{"key":"e_1_2_26_7_2","first-page":"202","volume-title":"Handbook of Veterinary Neurology","author":"Lorenz MD","year":"2004"},{"key":"e_1_2_26_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2005.tb02789.x"},{"key":"e_1_2_26_9_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2460\/javma.1999.215.07.956","article-title":"Inherited predisposition to myasthenia gravis in newfoundlands","volume":"215","author":"Lipsitz D","year":"1999","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_26_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2008.00627.x"},{"key":"e_1_2_26_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aem144"},{"issue":"2","key":"e_1_2_26_12_2","first-page":"50","article-title":"Clinical forms of acquired myasthenia gravis in dogs","volume":"11","author":"Dewey CW","year":"1997","journal-title":"25 cases (1988\u20131995)"},{"key":"e_1_2_26_13_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2833-09.2009"},{"key":"e_1_2_26_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.9.1417"},{"key":"e_1_2_26_15_2","first-page":"8635","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"256","author":"Tzartos SJ","year":"1982","journal-title":"J Biol Chem"},{"key":"e_1_2_26_16_2","first-page":"1747","article-title":"Autoreactive CD8+T cells in multiple sclerosis","volume":"128","author":"Friese MN","year":"2005","journal-title":"a new target for therapy?"},{"issue":"9","key":"e_1_2_26_17_2","first-page":"582","article-title":"Systemic lupus erythematosus and myasthenia gravis","volume":"119","author":"Herycek A.","year":"2009","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"e_1_2_26_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"e_1_2_26_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10143"},{"key":"e_1_2_26_20_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1967.sp008237"},{"key":"e_1_2_26_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1993.tb02685.x"},{"key":"e_1_2_26_22_2","volume-title":"Principles of Neural Science","author":"Kandel ER","year":"2000"},{"key":"e_1_2_26_23_2","first-page":"724","article-title":"Acethylcholinesterase inhibitors in myasthenia gravis","volume":"39","author":"Punga AR","year":"2009","journal-title":"to be or not to be?"},{"key":"e_1_2_26_24_2","first-page":"57","article-title":"B cells in the pathophysiology of autoimmune neurologic disorders","volume":"112","author":"Dalakas MC.","year":"2006","journal-title":"a credible therapeutic target"},{"issue":"3","key":"e_1_2_26_25_2","first-page":"12","article-title":"IVIg in other autoimmune neurological disorders","volume":"255","author":"Dalakas M.","year":"2008","journal-title":"current status and future prospects"},{"key":"e_1_2_26_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406233302507"},{"key":"e_1_2_26_27_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G501"},{"key":"e_1_2_26_28_2","first-page":"368","article-title":"Myasthenia gravis","volume":"39","author":"Shelton GD.","year":"1998","journal-title":"lessons from the past 10 years"},{"key":"e_1_2_26_29_2","first-page":"239","article-title":"Acquired myasthenia gravis","volume":"69","author":"Shelton GD.","year":"1999","journal-title":"what we have learned from experimental and spontaneous animal models"},{"issue":"11","key":"e_1_2_26_30_2","first-page":"1428","article-title":"Risk factors for acquired myasthenia gravis in dogs","volume":"211","author":"Shelton GD","year":"1997","journal-title":"1,154 cases (1991\u20131995)"},{"key":"e_1_2_26_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2009.00433.x"},{"issue":"9","key":"e_1_2_26_32_2","first-page":"809","article-title":"Thymectomy In fulminating myasthenia gravis of childhood","volume":"55","author":"Swaiman KF","year":"1972","journal-title":"Minn Med"},{"issue":"4","key":"e_1_2_26_33_2","first-page":"388","article-title":"Acute fulminating myasthenia gravis in children","volume":"63","author":"Bastedo DL.","year":"1950","journal-title":"Can Med Assoc J"},{"key":"e_1_2_26_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb05050.x"},{"issue":"4","key":"e_1_2_26_35_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2460\/javma.1990.197.04.488","article-title":"Acquired myasthenia gravis and cholangiocellular carcinoma in a dog","volume":"197","author":"Krotjel LJ","year":"1990","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_26_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0503-2"},{"key":"e_1_2_26_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1997.tb03492.x"},{"key":"e_1_2_26_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.03.004"},{"key":"e_1_2_26_39_2","first-page":"1029","article-title":"Paraneoplastic myasthenia gravis","volume":"15","author":"Skeie GO","year":"2008","journal-title":"immunologic and clinical aspects"},{"key":"e_1_2_26_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e3181870aa2"},{"issue":"12","key":"e_1_2_26_41_2","first-page":"1340","article-title":"Acquired myasthenia gravis in dogs part 1","volume":"19","author":"Dewey CW.","year":"1997","journal-title":"Compend Contin Educ Pract Vet"},{"key":"e_1_2_26_42_2","volume-title":"Veterinary Neuroanatomy and Clinical Neurology","author":"DeLahunta A.","year":"1983"},{"key":"e_1_2_26_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2003.tb02476.x"},{"key":"e_1_2_26_44_2","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2009.5.2.53"},{"key":"e_1_2_26_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.11.1054"},{"key":"e_1_2_26_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05440.x"},{"key":"e_1_2_26_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320419"},{"key":"e_1_2_26_48_2","first-page":"331","article-title":"Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin","volume":"66","author":"Williams CL","year":"1992","journal-title":"Lab Invest"},{"key":"e_1_2_26_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(00)00255-5"},{"key":"e_1_2_26_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-009-9274-0"},{"issue":"8","key":"e_1_2_26_51_2","first-page":"546","article-title":"Myasthenia gravis","volume":"21","author":"Hetherington KA","year":"2005","journal-title":"myasthenia vs. cholinergic crisis"},{"key":"e_1_2_26_52_2","first-page":"493","article-title":"Management of myasthenic conditions","volume":"22","author":"Argov Z.","year":"2009","journal-title":"nonimmune issues"},{"key":"e_1_2_26_53_2","first-page":"66","article-title":"The reactivity of the antistriational antibodies associated with thymoma and myasthenia gravis","volume":"27","author":"Peers J","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_26_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171208"},{"key":"e_1_2_26_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.08.011"},{"key":"e_1_2_26_56_2","first-page":"273","article-title":"Seronegative myasthenia gravis","volume":"13","author":"Padua V","year":"2006","journal-title":"comparison of neurophysiological picture in MuSK+ and MuSK\u2212 patients"},{"key":"e_1_2_26_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183145.91579.74"},{"key":"e_1_2_26_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092"},{"key":"e_1_2_26_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-007-0734-0"},{"key":"e_1_2_26_60_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.144.3.726"},{"key":"e_1_2_26_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013"},{"key":"e_1_2_26_62_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903555943"},{"key":"e_1_2_26_63_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jneuroim.2007.01.010","article-title":"Effect of sera from AChR\u2010antibonndy negative myasthenia gravis patients on AChR and MuSK in cell cultures","volume":"185","author":"Farrugia ME","year":"2007","journal-title":"J Neuroimmunol"},{"key":"e_1_2_26_64_2","first-page":"2139","article-title":"Spontaneous remission in canine myasthenia gravis","volume":"57","author":"Shelton GD","year":"2001","journal-title":"implications for assessing human MG therapies"},{"issue":"6","key":"e_1_2_26_65_2","first-page":"664","article-title":"Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis","volume":"236","author":"Dewey CW","year":"2010","journal-title":"27 cases (1999\u20132008)"},{"key":"e_1_2_26_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20935"},{"key":"e_1_2_26_67_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.23.12.1273"},{"key":"e_1_2_26_68_2","first-page":"374","volume-title":"BSAVA Manual of Canine and Feline Neurology","author":"Platt SR","year":"2004"},{"key":"e_1_2_26_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1220"},{"key":"e_1_2_26_70_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.012"},{"key":"e_1_2_26_71_2","first-page":"370","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse","volume":"97","author":"Lingberg C","year":"1998","journal-title":"a double-blind study"},{"issue":"1","key":"e_1_2_26_72_2","first-page":"47","article-title":"Acquired myasthenia gravis in dogs\u2010part II","volume":"20","author":"Dewey CW.","year":"1998","journal-title":"Compend Contin Educ Pract Vet"},{"key":"e_1_2_26_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1992.tb00340.x"},{"key":"e_1_2_26_74_2","first-page":"588","article-title":"Immunosuppressive drugs","volume":"505","author":"Matell G.","year":"1987","journal-title":"azathioprine in the treatment of myasthenia gravis"},{"key":"e_1_2_26_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.01.001"},{"key":"e_1_2_26_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200005)47:5<682::AID-ANA24>3.0.CO;2-Z"},{"key":"e_1_2_26_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.144980"},{"key":"e_1_2_26_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005224.pub2"},{"key":"e_1_2_26_79_2","doi-asserted-by":"publisher","DOI":"10.5326\/15473317-35-5-396"},{"key":"e_1_2_26_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb00771.x"},{"key":"e_1_2_26_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02130.x"},{"issue":"1","key":"e_1_2_26_82_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1749-6632.1998.tb10990.x","article-title":"Analysis of risk factors for acquired myasthenia in dogs","volume":"841","author":"Shelton GD","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_2_26_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_2_26_84_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.3.448"},{"issue":"6","key":"e_1_2_26_85_2","first-page":"1203","article-title":"Mycophenolate mofetil for myasthenia gravis","volume":"4","author":"Heatwole C","year":"2008","journal-title":"a clear and present controversy"},{"issue":"1","key":"e_1_2_26_86_2","first-page":"94","article-title":"Mycophenolate mofetil","volume":"56","author":"Chaundhry V","year":"2001","journal-title":"a safe and promising immunosuppressant in neuromuscular diseases"},{"key":"e_1_2_26_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2000.tb00009.x"},{"key":"e_1_2_26_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21306"},{"key":"e_1_2_26_89_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"e_1_2_26_90_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_26_91_2","first-page":"303","article-title":"Myasthenia gravis","volume":"5","author":"Sieb JP.","year":"2005","journal-title":"emerging new therapy options"},{"key":"e_1_2_26_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)01373-6"},{"key":"e_1_2_26_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(95)00009-Q"},{"key":"e_1_2_26_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10133"},{"key":"e_1_2_26_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10472"},{"key":"e_1_2_26_96_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.000"},{"key":"e_1_2_26_97_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000147242.92691.71"},{"key":"e_1_2_26_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_26_99_2","doi-asserted-by":"publisher","DOI":"10.1354\/vp.42-4-468"},{"issue":"5","key":"e_1_2_26_100_2","first-page":"S76","article-title":"Myasthenia gravis with thymoma","volume":"48","author":"Loveless RE","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_26_101_2","first-page":"1007","article-title":"Thymoma in dogs","volume":"205","author":"Atwater SW","year":"1994","journal-title":"23 cases (1980\u20131991)"},{"key":"e_1_2_26_102_2","first-page":"890","article-title":"Consensus statement","volume":"40","author":"Donofrio PD","year":"2009","journal-title":"the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM AD Hoc Committee"},{"key":"e_1_2_26_103_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1154315"},{"key":"e_1_2_26_104_2","first-page":"187","article-title":"Intravenous immunoglobulin suppresses experimental myasthenia gravis","volume":"176","author":"Zhu KY","year":"2006","journal-title":"immunological mechanisms"},{"key":"e_1_2_26_105_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0358.x"},{"issue":"4","key":"e_1_2_26_106_2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1939-1676.2007.tb03010.x","article-title":"Treatment of severe immune\u2010mediated thrombocytopenia with human IV immunoglobulin in 5 dogs","volume":"21","author":"Bianco D","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"6","key":"e_1_2_26_107_2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1939-1676.2006.tb00770.x","article-title":"The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog","volume":"20","author":"Rahilly LJ","year":"2006","journal-title":"J Vet Intern Med"},{"key":"e_1_2_26_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1997.tb00475.x"},{"key":"e_1_2_26_109_2","first-page":"103","article-title":"Therapeutic plasma exchange in the treatment in neuroimmunologic disorders","volume":"36","author":"Y\u00fbcesan C","year":"2007","journal-title":"review of 50 cases"},{"key":"e_1_2_26_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2009.00431.x"},{"issue":"2","key":"e_1_2_26_111_2","first-page":"109","article-title":"Therapeutic plasma exchange in patients with neurologic diseases","volume":"38","author":"Kaynar L","year":"2008","journal-title":"retrospective multicenter study"},{"key":"e_1_2_26_112_2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2460\/javma.1990.196.08.1276","article-title":"Clinical remission following plasmapheresis and corticosteroid treatment in a dog with acquired myasthenia gravis","volume":"196","author":"Bartges JW","year":"1990","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_26_113_2","first-page":"323","article-title":"Possible therapeutic vaccines for canine myasthenia gravis","volume":"21","author":"Galin FS","year":"2007","journal-title":"implications for the human disease and associated fatigue"}],"container-title":["Journal of Veterinary Emergency and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-4431.2011.00636.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-4431.2011.00636.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T17:01:34Z","timestamp":1712422894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-4431.2011.00636.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1476-4431.2011.00636.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-4431.2011.00636.x","archive":["Portico"],"relation":{},"ISSN":["1479-3261","1476-4431"],"issn-type":[{"value":"1479-3261","type":"print"},{"value":"1476-4431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]},"assertion":[{"value":"2011-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}